Home / News / CMS Belgium advises Graftys and its shareholders on...

CMS Belgium advises Graftys and its shareholders on its acquisition of Biologics4life

17/11/2021

CMS Belgium advised Graftys and its shareholders, a Belgian Medtech company specializing in the development and manufacturing of synthetic bone biomaterials, on its acquisition of the French company Biologics4life, which also produces biomaterials for bone regeneration. Through this merger, the two companies can form an international group specializing in biomaterials for bone grafts.

The CMS team advising Graftys and its shareholders was comprised David Prync, Jean-François Goffin and Alinna Hu.

Related people

Portrait ofDavid Prync
David Prync
Partner
Brussels
Portrait ofJean-François Goffin
Jean-François Goffin
Partner
Brussels
Alinna Hu